Inmune Bio Files 8-K for Financials and Exhibits
Ticker: INMB · Form: 8-K · Filed: Sep 17, 2024 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: INMB
TL;DR
INMB filed an 8-K for routine financial updates and exhibits.
AI Summary
On September 17, 2024, Inmune Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather than a specific material event. No new material agreements, executive changes, or significant financial transactions were detailed in the provided excerpt.
Why It Matters
This filing serves as a standard update for investors, providing necessary financial information and exhibits as required by the SEC. It confirms the company is meeting its reporting obligations.
Risk Assessment
Risk Level: low — The filing appears to be a standard, routine disclosure of financial statements and exhibits, not indicating any immediate new risks or significant events.
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- September 17, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Inmune Bio, Inc.?
The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of September 17, 2024.
What is Inmune Bio, Inc.'s state of incorporation?
Inmune Bio, Inc. is incorporated in Nevada.
What is the principal executive office address for Inmune Bio, Inc.?
The principal executive office is located at 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What is the SIC code for Inmune Bio, Inc.?
The Standard Industrial Classification (SIC) code for Inmune Bio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
When is Inmune Bio, Inc.'s fiscal year end?
Inmune Bio, Inc.'s fiscal year ends on December 31.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-17 16:00:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
Filing Documents
- ea0214852-8k_inmune.htm (8-K) — 24KB
- ea021485201ex99-1_inmune.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-24-079445.txt ( ) — 224KB
- inmb-20240917.xsd (EX-101.SCH) — 3KB
- inmb-20240917_lab.xml (EX-101.LAB) — 33KB
- inmb-20240917_pre.xml (EX-101.PRE) — 22KB
- ea0214852-8k_inmune_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On September 17, 2024, INmune Bio Inc. (the "Company"), issued a press release announcing that results of additional analysis of blinded data from its AD02 Phase II Alzheimer's Disease ("AD") trial demonstrated exceptional performance of the novel cognitive measure EMACC, as well as highly significant correlation between EMACC and the clinical dementia rating sum of boxes, the accepted endpoint for AD trials. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial statements and Exhibits
Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release dated September 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: September 17, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2